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Abstract
Objective: Psychosocial interventions can reduce cancer-related fatigue effectively. How-
ever, it is still unclear if intervention effects differ across subgroups of patients. These
meta-analyses aimed at evaluating moderator effects of (a) sociodemographic characteris-
tics, (b) clinical characteristics, (c) baseline levels of fatigue and other symptoms, and
(d) intervention-related characteristics on the effect of psychosocial interventions on
cancer-related fatigue in patients with non-metastatic breast and prostate cancer.
Methods: Data were retrieved from the Predicting OptimaL cAncer RehabIlitation
and Supportive care (POLARIS) consortium. Potential moderators were studied with
meta-analyses of pooled individual patient data from 14 randomized controlled trials
through linear mixed-effects models with interaction tests. The analyses were con-
ducted separately in patients with breast (n = 1091) and prostate cancer (n = 1008).
Results: Statistically significant, small overall effects of psychosocial interventions on
fatigue were found (breast cancer: β = −0.19 [95% confidence interval (95%CI) = −0.30;
−0.08]; prostate cancer: β = −0.11 [95%CI = −0.21; −0.00]). In both patient groups, inter-
vention effects did not differ significantly by sociodemographic or clinical characteristics,
nor by baseline levels of fatigue or pain. For intervention-related moderators (only tested
among women with breast cancer), statistically significant larger effects were found for
cognitive behavioral therapy as intervention strategy (β = −0.27 [95%CI = −0.40; −0.15]),
fatigue-specific interventions (β = −0.48 [95%CI = −0.79; −0.18]), and interventions that
only targeted patients with clinically relevant fatigue (β = −0.85 [95%CI = −1.40; −0.30]).
Conclusions: Our findings did not provide evidence that any selected demographic
or clinical characteristic, or baseline levels of fatigue or pain, moderated effects of
psychosocial interventions on fatigue. A specific focus on decreasing fatigue seems
beneficial for patients with breast cancer with clinically relevant fatigue.
K E YWORD S
breast cancer, cancer, fatigue, individual patient data meta-analysis, moderators, oncology,
prostate cancer, psycho-oncology, psychosocial interventions
1 | BACKGROUND
Fatigue is one of the most commonly reported adverse effects of can-
cer and cancer treatment.1 Cancer-related fatigue is associated with a
compromised quality of life and can persist for many years after treat-
ment completion.1 Several interventions have been developed to
manage cancer-related fatigue. Results of a recent meta-analysis indi-
cated that psychosocial interventions (like cognitive behavioral
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therapy, CBT and stress management) had statistically significant
moderate effects on cancer-related fatigue, comparable with exercise
interventions, but larger than pharmaceutical interventions.2
It is still unclear what types of evidence-based psychosocial inter-
ventions work best on fatigue for which subgroups of patients with
cancer.3 Therefore, characteristics that influence the direction or mag-
nitude of the effect of such interventions on cancer-related fatigue
(moderators of intervention effects) need to be identified.3 Thus far,
meta-analyses on moderators of interventions of cancer-related
fatigue have been based on pooled aggregate data of individual ran-
domized controlled trials (RCTs).2,4-6 Inherent to the use of aggregate
data is the loss of a large amount of valuable information about indi-
vidual scores and characteristics, and an increased risk of ecological
bias.7
The use of individual patient data instead of aggregate data in
meta-analyses allows for a more reliable and detailed examination of
moderators of intervention effects.7 Collaboration with other
researchers and sharing of data are needed to realize a meta-analysis
based on individual patient data. Such an initiative was undertaken by
the Predicting OptimaL cAncer RehabIlitation and Supportive care
(POLARIS) consortium.8 This collaborative group has been established
to share data of RCTs that evaluated the effects and moderators of
exercise and psychosocial interventions for patients with cancer.8 Pre-
vious individual patient data meta-analyses from the POLARIS study
examined the effects and moderators of exercise and psychosocial
interventions on health-related quality of life.9-14
This paper will specifically be focused on psychosocial interven-
tions and will report on the first individual patient data meta-analyses
to explore moderators of the effect of psychosocial interventions on
cancer-related fatigue. Previous RCTs and meta-analyses of aggregate
(study-level) data have reported more favorable outcomes of psycho-
social interventions in patients with cancer in case of a younger or
older age (contradictory findings), no cancer recurrence, treatment
with chemotherapy, a longer intervention duration, and higher base-
line levels of depression and distress.15,16 Potential moderators in the
current study were selected based on this literature and categorized
into sociodemographic, clinical and intervention-related factors, and
baseline levels of symptoms.14
We precluded heterogeneity in tumor type by conducting sepa-
rate analyses for patients with breast cancer and prostate cancer. Spe-
cific knowledge on these two groups could add to the growing
literature aimed at personalizing psychosocial interventions for
patients with cancer. Comparison of patients with breast and prostate
cancer made it possible to conduct separate analyses for men and
women. We also chose to select patients with non-metastatic cancer,
based on another meta-analysis that demonstrated larger intervention
effects on cancer-related fatigue in patients with non-metastatic com-
pared to metastatic cancer.2 In this way, we aimed to study moderator
effects in two relatively homogeneous groups of patients with cancer.
The aims of the current individual patient data meta-analyses
were to examine the moderator effects of1; sociodemographic
characteristics,2 clinical characteristics,3 baseline levels of fatigue and
other symptoms (ie, depression, anxiety, pain, and insomnia), and4
intervention-related characteristics on the effect of psychosocial
interventions on fatigue in patients with non-metastatic breast and
prostate cancer. Psychosocial interventions could be fatigue-specific
or more broadly focused.
2 | METHODS
2.1 | Protocol and registration
This section is written in accordance with the Preferred Reporting
Items for Systematic review and Meta-Analyses of Individual Partici-
pant Data (PRISMA- IPD).17 Before commencing in February 2013,
the POLARIS study was registered in the International Prospective
Register of Systemic Reviews (PROSPERO, reference no. CRD
42013003805). This section provides a summary of the design and
procedures of the POLARIS study. A more detailed description of the
study protocol has been published.8
2.2 | Study procedure
Data were obtained from the POLARIS database which includes RCTs
that: (a) evaluated the effects of physical activity and/or psychosocial
interventions; (b) included quality of life as primary or secondary out-
come; (c) were conducted among adult patients with cancer; and
(d) compared an intervention group with a waiting list, attention or
usual care control group.8 All principal investigators (PIs) of eligible
RCTs were invited to participate in the POLARIS consortium and to
share data. This has resulted in PIs of 22 out of 61 eligible RCTs evalu-
ating psychosocial interventions who have shared anonymized indi-
vidual patient data (response rate 36%).14 Outcomes of these RCTs
were compared with RCTs of which individual patient data were not
shared. This comparison showed no significant differences in effects
on quality of life, which supported the representativeness of this sam-
ple for all eligible RCTs.14 The search strategy and data extraction
have been described.14 Participating PIs signed a data sharing agree-
ment statement, in which they agreed with the POLARIS policies. All
individual RCTs had received approval from local ethics committees.
After checking for completeness and correctness, shared databases
were recoded and harmonized into the POLARIS database.
For the current study, we included RCTs that had examined the
effects of (a) psychosocial interventions on (b) fatigue in (c) women
with breast cancer or men with prostate cancer and (d) with non-
metastatic disease. Exercise interventions were not included. Psycho-
social interventions did not need to be fatigue-specific. This means
that more broadly focused interventions were also eligible. The Cun-
ningham criteria were used to classify all psychosocial interventions in
five categories in hierarchical order, from little to more active patient
participation.18 These categories are providing information, emotional
support, coping skills training, psychotherapy and, spiritual/existential
therapy. Interventions needed to be at least a coping skills training, so
interventions from the first two categories were excluded. This means
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that cognitive and/or behavioral methods must have been applied to
change patients' cognitions or behaviors to improve their coping strat-
egies.18 An overview from a review on psychosocial interventions in
patients with cancer was used to specify the intervention strategies
that were applied.19 The quality of the included studies was rated
with the “risk-of-bias” tool of the Cochrane Collaboration by two
authors independently20 and has been reported previously.14 This
quality rating was based on the aspects random sequence generation,
allocation concealment, incomplete outcome, and incomplete
reporting.
2.3 | Potential moderators
Potential moderators that were tested were based on previous, origi-
nal RCTs or meta-analyses in patients with cancer.14 Patient charac-
teristics were only included if individual data were available for at
least 50% of patients, which was the case for age (continuous and
groups of <50/50-70/≥70 years), married or living with a partner
(yes/no), and education level (low/middle or high). Different cancer
treatment types were also included as potential moderators (surgery,
chemotherapy, radiotherapy and hormone therapy: yes/no), as well as
continuous baseline levels of fatigue and other symptoms (depression,
anxiety, pain, and insomnia). Fatigue was also tested as a dichotomous
variable by dividing patients in a group with and without clinically rel-
evant levels of fatigue at baseline. This division was based on the
questionnaires for which a cut-off score was available (score ≤50 on
Short Form-36 Item Health Survey vitality subscale (SF-36),21 score
≥40 on European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire – Core 30 fatigue subscale (EORTC-
QLQ),22 and score ≥35 on Checklist Individual Strength, subscale
Fatigue Severity (CIS-fatigue)23).
The potential intervention-related moderator “timing of delivery
of the intervention” was divided into during vs post cancer treatment.
Data on this variable varied within included studies, so analysis of this
potential intervention-related moderator was based on individual
patient data. Women receiving hormone therapy for breast cancer
were categorized as being post cancer treatment, as hormone therapy
can continue for five years after completion of other types of cancer
treatments. Men on androgen deprivation therapy for prostate cancer
were categorized as being during cancer treatment.
Data on other potential intervention-related moderators did not
vary within studies, so its analyses could only be based on aggregate
data. We chose to distinguish CBT as potential moderator from the
other intervention strategies because (a) CBT was tested in most of
the available studies (7 of 12) and (b) CBT was shown to be most
effective in a recent meta-analysis compared to other strategies.1 By
comparing CBT with the other intervention strategies, we aimed to
build further on the existing literature. Other included intervention-
specific characteristics were:
1. Selection of patients with clinically relevant levels of fatigue as part
of the eligibility criteria (yes vs no)
2. Fatigue-specific intervention (ie, specifically aimed at reducing
fatigue) (yes vs no)
3. Intervention duration (<12 weeks vs ≥12 of weeks, median split
drawn from the current study)
4. Number of sessions (<6 sessions vs ≥6 sessions, median split
drawn from the current study)
5. Professional guidance (yes vs no)
6. Leading profession (psychologist vs other)
7. Delivery mode (individual vs couple or group)
8. Type of delivery (face-to-face vs telephone sessions)
2.4 | Statistical analysis
All analyses were conducted separately for patients with breast and
prostate cancer. Z-scores were used to pool outcomes of different
measures of fatigue (calculated by subtracting the mean score at base-
line from the individual score, divided by the mean SD at baseline for
each fatigue instrument). If more than one fatigue instrument was
used, a fatigue-specific questionnaire was chosen. If this was not
available, the fatigue scale of a cancer-specific quality of life question-
naire was used. In case more than one fatigue-specific or cancer-
specific quality of life questionnaire were used in one study, we
selected the questionnaire that was used most frequently in all
included studies to increase power for subgroup analyses. The same
procedure was used to pool outcomes of different instruments to
measure four other symptoms that were explored as potential moder-
ators (depression, anxiety, pain, and insomnia).
A one-step complete-case individual patient data meta-analysis
was conducted to calculate the overall effect of psychosocial inter-
ventions on fatigue (measured at the end of the intervention) using
linear mixed model analyses, adjusted for the baseline level of fatigue.
The independent variables in the model were the allocated condition
(psychosocial intervention or control group), and the baseline level of
fatigue. We reported the regression coefficients and corresponding
95% CI that represent the between-group difference in z-scores, and
correspond a Cohen's d effect size (0.2 to 0.5 was considered as small,
0.5 to 0.8 as moderate, ≥0.8 as large).24
Sociodemographic, treatment characteristics and pooled z-scores
for baseline levels of anxiety, depression, pain and insomnia were
tested as potential moderators by adding each patient characteristic
and its interaction term with the intervention as independent vari-
ables into the model. To prevent ecological bias, all individual values
were centered around the mean values at the study level. If there was
a significant improvement of the model fit according to the likelihood
ratio test (LRT) after adding the interaction term, a patient characteris-
tic was considered to be a relevant moderator. Each potential modera-
tor was tested in a separate model.
The same method was followed to test intervention characteris-
tics as potential moderators, but individual values did not need to be
centered because there was no variation in values within studies.
P-values below .05 were considered as statistically significant. All ana-
lyses were conducted with IBM SPSS Statistics 24.0.
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3 | RESULTS
3.1 | Flow chart of patient inclusion
Authors of 22 psychosocial intervention studies had shared individual
patient data in the POLARIS consortium. Eight of these 22 studies
were not eligible because fatigue was not measured (k = 4),25-28 no
patients with non-metastatic disease were included or status of
metastases was unknown (k = 2),29,30 no patients with breast or pros-
tate cancer were included (k = 1),31 or the tested intervention was not
at least a coping skills training intervention (k = 1).32 Fourteen studies
were eligible with a total of 2497 patients, of which 112 patients with
a tumor type other than breast or prostate cancer were excluded, as
well as 252 patients with metastases at baseline and 34 patients with
an unknown status regarding metastases. Finally, individual data of
2099 patients from 14 studies were included in the analyses
(Figure A1).33-46
3.2 | Study characteristics
Ten of the 14 studies included patients with breast cancer,33-42 two
studies only included patients with prostate cancer,43,44 and the other
two studies included patients with both tumor types.45,46 Most stud-
ies were conducted in the United States (k = 4)37,38,40,44 and the Neth-
erlands (k = 4).34,36,42,45 Sample sizes ranged from 3036,40 to 734.43
Patients with clinically relevant levels of fatigue were only selected in
one of the 14 studies.36 Five different self-report questionnaires were
used to measure fatigue, with the SF-36 vitality subscale as most fre-
quently used questionnaires in five studies.34,39,40,43,44 A usual
care33,35,38-40,42-46 or waiting list control condition was used as con-
trol group34,36,37,41 (Table 1).
3.3 | Patient characteristics
The sample of women with breast cancer consisted of 1091 patients
with a mean age of 53 years (SD = 9.7). The majority of these patients
was married or living with a partner (n = 714, 76%) and had a low or
middle education level (n = 437, 62%). Almost all patients were
treated with surgery (n = 1087, 99.7%). The majority of patients had
also received radiotherapy (n = 894, 82%), chemotherapy (n = 715,
66%) and/or hormone therapy (n = 595, 60%) (Table 2).
The sample of men with prostate cancer included 1008 patients
with a mean age of 62 years (SD=8). The majority of these patients
was married or living with a partner (n = 836, 87%) and had a high
education level (n = 506, 53%). Half of patients were treated with sur-
gery (n = 495, 50%) and less than half were treated with radiotherapy
(n = 431, 44%) and/or hormone therapy (n = 301, 30%) (Table 2).
Mean levels of fatigue and other symptoms are shown for each
different questionnaire in Tables A1 and A2 (Appendix). Examining
the subsample of patients in which a questionnaire with validated cut-
off score for fatigue was used, 27% of patients with breast cancer
(n = 299) and 41% of patients with prostate cancer (n=421) reported
clinically relevant levels of fatigue at baseline.
3.4 | Intervention characteristics
Two of the 14 studies tested an intervention that was specifically
aimed at treating cancer-related fatigue.36,45 The intervention was
provided post cancer treatment in 7 of 14 studies.34-36,38,41,42 The
duration of the interventions ranged from four days35 to 30 weeks,45
with a mean duration of 12 weeks. The most commonly applied inter-
vention strategy (7 of 14 studies) was CBT.34,36,39,41-43,45,46 Other
intervention strategies were dyadic therapy,40,44 problem solving
therapy,33 expressive writing,35 social cognitive therapy,37 and coping
skills intervention.38 Two interventions were self-guided,35,42 of which
one was an e-health intervention.42 The other interventions were pro-
fessionally guided and had a mean of seven sessions (range 346 to
1336) and were mostly guided by a psychologist (k = 5),36,39,41,45,46
delivered individually (k = 5)33,36,43,45,46 and face-to-face
(k = 10)33,34,36,37,39-41,44-46 (Table 1).
3.5 | Overall intervention effect
Compared to control conditions, psychosocial interventions had sta-
tistically significant, small overall effects on fatigue in patients with
breast cancer (β = −0.19 [95% confidence interval (95%CI) = −0.30;
−0.08]) and prostate cancer (β = −0.11 [95%CI = −0.21; −0.00]).
3.6 | Potential moderators based on individual
patient data
Age (continuous and categorical [<50/50-70/≥70 years]), being mar-
ried and/or living with a partner, education level, type of cancer treat-
ment, and baseline levels of fatigue (continuous and dichotomous)
and pain did not significantly moderate the intervention effect on
fatigue, neither in women with breast cancer nor in men with prostate
cancer. Baseline levels of depression, anxiety, and insomnia were only
tested as moderators in women with breast cancer and were also not
statistically significant (Table 3).
3.7 | Potential intervention-related moderators in
patients with breast cancer
Given the small number of studies among patients with prostate can-
cer (k = 4), all intervention-related moderators were only explored for
studies among patients with breast cancer (k = 12). Effects on fatigue
were significantly larger (P = .02) when CBT was used as a interven-
tion strategy compared with other intervention strategies like expres-
sive writing and social cognitive therapy (respectively β = −0.27 [95%
CI = −0.40; −0.15] vs β = 0.03 [95%CI = −0.20; 0.25]). The one study
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that only included patients with clinically relevant levels of fatigue27
showed a clearly larger intervention effect on fatigue (p=0.02) com-
pared to studies that included all patients irrespective of their fatigue
level (β = −0.85 [95%CI = −1.40; −0.30] vs β = −0.17 [95%CI = −0.28;
−0.05]). Additionally, the two interventions that were specifically
aimed at reducing fatigue27,36 had significantly larger effects on
fatigue (P = .03) than generic interventions or interventions that were
aimed at other symptoms like menopausal symptoms or psychological
distress (respectively β = −0.48 [95%CI = −0.79; −0.18] vs β = −0.15
[95% CI = −0.27; −0.03]). The variables related to timing of delivery
of the intervention, intervention duration, number of sessions, profes-
sional guidance, leading profession, delivery mode, and type of deliv-
ery did not significantly moderate the intervention effect (Table 4).
4 | DISCUSSION
These individual patient data meta-analyses showed statistically sig-
nificant, small overall effects of psychosocial interventions on fatigue
in patients with breast and prostate cancer. Intervention effects did
TABLE 2 Patient characteristics at
baseline
Patients with breast cancer Patients with prostate cancer
Intervention Control Intervention Control
(n = 565) (n = 526) (n = 500) (n = 508)
Sociodemographic characteristics
Age, mean (SD) y 52.7 (9.7) 53.3 (9.7) 62.2 (8.1) 61.9 (8.0)
Age in categories, n (%)
<50 y 204 (36) 208 (40) 29 (6) 24 (5)
50-70 y 322 (57) 284 (54) 373 (75) 395 (78)
≥70 y 38 (7) 32 (6) 98 (20) 89 (18)
Unknown 1 (<1) 2 (<1) - -
Married/living with a partner, n (%)
Yes 381 (67) 333 (63) 414 (83) 422 (83)
No 112 (20) 119 (23) 63 (13) 64 (13)
Unknown 72 (13) 74 (14) 23 (5) 22 (4)
Education level, n (%)
Low/Middle 210 (37) 227 (43) 229 (46) 227 (45)
High 138 (24) 135 (26) 247 (49) 259 (51)
Unknown 217 (38) 164 (31) 24 (5) 22 (4)
Cancer treatment type
Surgery, n (%)
Yes 561 (99) 526 (100) 229 (46) 266 (52)
No 4 (1) - 259 (52) 237 (47)
Unknown - - 12 (2) 5 (1)
Radiotherapy, n (%)
Yes 462 (82) 432 (82) 211 (42) 220 (43)
No 100 (18) 94 (18) 272 (54) 280 (55)
Unknown 3 (<1) - 17 (3) 8 (2)
Chemotherapy, n (%)
Yes 360 (64) 355 (68) - -
No 204 (36) 171 (33) 500 (100) 508 (100)
Unknown 1 (<1) - - -
Hormone therapy, n (%)
Yes 296 (52) 299 (57) 146 (29) 155 (31)
No 219 (40) 177 (34) 339 (68) 345 (68)
Unknown 50 (9) 50 (10) 15 (3) 8 (2)
Note: Baseline characteristics did not differ significantly between the intervention and control group in
(a) patients with breast and (b) prostate cancer.
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not differ significantly between patients with different socio-
demographic characteristics, clinical characteristics, baseline levels of
fatigue and pain. In patients with breast cancer, we observed strongest
effects of CBT, fatigue-specific interventions and interventions that only
targeted patients with clinically relevant levels of fatigue.
Potential moderators of psychosocial interventions for cancer-
related fatigue have been studied in only a few previous meta-
analyses based on aggregate data that included patients with various
cancer types.2,4-6 With regard to our sociodemographic characteris-
tics, only age has previously been explored as a potential moderator.
In line with our results, age did not significantly moderate intervention
effects.2 Based on our data, there is no evidence that specific demo-
graphic or clinical characteristics are of importance for the effect of
interventions on cancer-related fatigue.
TABLE 3 Potential moderators of the effect of psychosocial
interventions on cancer-related fatigue on patient-level
χ2 [df], P-value
Patients with breast cancer
Socio-demographic characteristics
Age (continuous) 3.23 [1], .07
Age (<50 vs 50-70 vs ≥70 y) 4.42 [2], .11
Having a partner (yes vs no) 0.35 [1], .55
Education level (low vs middle or high) 0.40 [1], .53
Cancer treatment type
Surgery (yes vs no) 2.61 [1], .11
Radiotherapy (yes vs no) 0.64 [1], .42
Chemotherapy (yes vs no) 0.04 [1], .84
Hormone therapy (yes vs no) 0.02 [1], .89
Baseline level of fatigue and other symptoms
Fatigue (continuous) 1.53 [1], .22
Clinically relevant fatigue (yes vs no) 1.10 [1], .29
Depression (continuous) 0.01 [1], .94
Anxiety (continuous) 0.02 [1], .89
Pain (continuous) 2.48 [1], .12
Insomnia (continuous) 1.31 [1], .25
Patients with prostate cancer
Socio-demographic characteristics
Age (continuous) 0.01 [1], .91
Age (<50 vs 50-70 vs ≥70 y) 0.78 [2], .68
Partner status (yes vs no) 3.44 [1], .06
Education level (low vs middle/high) 0.26 [1], .61
Type of cancer treatment
Surgery (yes vs no) 0.21 [1], .65
Radiotherapy (yes vs no) 0.14 [1], .71
Hormone therapy (yes vs no) 0.19 [1], .66
Baseline level of fatigue and other symptomsa
Fatigue (continuous) 0.19 [1], .66
Clinically relevant fatigue (yes vs no) 0.04 [1], .84
Pain (continuous) 0.19 [1], .66
Note: Chi-square test with corresponding degrees of freedom (df) and
P-values of the likelihood ratio test of the difference between models with
and without interactions (χ2) are presented. All analyses are controlled for
the level of fatigue at baseline.
aAs data on the symptoms depression, anxiety, and insomnia were admin-
istered in only 7% of patients with prostate cancer, these variables were
not tested as moderators in this patient sample.
TABLE 4 Intervention-related moderators of psychosocial








therapy (k = 7)
−0.27 (−0.40; −0.15)*
Other (k = 5) 0.03 (−0.20; 0.25)




Yes (k = 2) −0.85 (−1.40; −0.30)*




Yes (k = 1) −0.48 (−0.79; −0.18)*
No (k = 11) −0.15 (−0.27; −0.03)*





[k = 6] vs ≥12 wk [k = 6])
1.32 [1], .25
Number of sessions (<6
[k = 5] vs ≥6 [k = 7])
0.41 [1], .52
Professional guidance (yes
[k=10] vs no [k = 2])
2.91 [1], .09
Leading profession
(psychologist [k = 5] vs
other [k = 5])b
2.45 [1], .12
Delivery mode (individual
[k = 4] vs couple or
group [k = 6])b
3.34 [1], .07
Type of delivery (face-to-
face [k = 9] vs telephone
[k = 1])b
0.76 [1], .38
Note: The table presents regression coefficients (β) with 95% confidence
intervals (CI) of the effect of psychosocial interventions stratified per
intervention-related moderator subgroup, and chi-square tests (χ2) with
corresponding degrees of freedom (df) and P-values of the likelihood ratio
test of the difference between models with and without interaction term.
All analyses are based on study-level data and controlled for the level of
fatigue at baseline.
Abbreviations: k = number of studies; n = number of participants.
aAs data on this variable varied within studies, its analysis was based on
individual patient data.
bData of studies testing self-guided interventions were excluded.
*P < .05.
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Our finding that CBT was more effective than other psychosocial
intervention strategies in patients with breast cancer corresponds
with a previous meta-analysis.2 It should be noted that subcategories
of other interventions have encompassed a variety of different inter-
vention strategies. However, according to our eligibility criteria, all
intervention strategies were focused on the acquisition of skills aimed
at cognitive or behavioral change.16 In this sense, the interventions in
the other category were comparable. Our sample size was too small
to explore specific components or ingredients within intervention
strategies. This is important for a further improvement of interven-
tions for cancer-related fatigue. Head-to-head comparisons could also
provide more insight into the effectiveness of different intervention
strategies.
Other significant moderators of the intervention effect in
patients with breast cancer were the delivery of a fatigue-specific
intervention and the selection of patients with clinically relevant
levels of fatigue at baseline. A higher effectiveness of fatigue-specific
interventions was also reported in a previous meta-analysis of
Kangas et al,4 showing a larger effect size for psychosocial interven-
tions that included cancer-related fatigue as a specific aim. A similar
conclusion was drawn in a Cochrane systematic review that showed
a higher effectiveness for fatigue-specific interventions compared to
non-specific interventions.47 Results of other meta-analyses have
also suggested that patients with higher fatigue levels benefit more
from interventions for fatigue than patients without significant
fatigue levels.12,48 In the present meta-analyses, less than half the
patients reported clinically relevant levels of fatigue at baseline (27%
of patients with breast cancer and 41% of patients with prostate can-
cer). This probably is an important reason for the relatively small
overall effect size observed compared to previous meta-analyses.2,5
It might also explain why mean baseline levels of fatigue and other
symptoms were not significant moderators of the intervention effect
(against expectations). As severe fatigue is more often reported by
patients treated with chemotherapy,1 we could have expected that
interventions for fatigue were more effective in these patients. This
was not the case, which may have to do with the relatively low num-
ber of patients with clinically relevant baseline levels of fatigue
as well.
The present study focused on patients with breast cancer or
prostate cancer, which reflects the vast majority of studies that
have been conducted so far. There was a lack of eligible studies in
the POLARIS database to enable analyses in patients with other
types of cancer. Future research will be needed to examine if our
findings can be generalized to patients with other types of cancer.
Further, we only tested single interactions; however, these interac-
tions are probably part of a more complex network of interactions
related to fatigue and other symptoms that still need to be
unraveled. Further exploration of relevant interactions is important
to better understand what types of interventions are most effective
for patients with cancer-related fatigue. Intervention-specific vari-
ables could only be tested in patients with breast cancer, but not in
patients with prostate cancer due to the limited number of studies
in the latter group.
5 | CONCLUSIONS
Our results showed that the effect of psychosocial interventions on
fatigue in patients with breast and prostate cancer was not signifi-
cantly moderated by any sociodemographic characteristics, clinical
characteristic, or baseline levels of fatigue or pain. In patients with
breast cancer, larger effects were found for CBT as intervention strat-
egy, fatigue-specific interventions, and interventions that only
targeted patients with clinically relevant levels of fatigue.
5.1 | Study limitations
The findings among patients with breast cancer of significant modera-
tor effects of the delivery of a fatigue-specific intervention and selec-
tion of patients with clinically relevant fatigue must be interpreted
with caution, because these factors were assessed in only a few RCTs
that tested the same intervention protocol.36,45 This means that these
findings may be confounded by other intervention characteristics,
such as the content of the intervention or the expertise of the trained
therapists who provided the intervention at a specialized treatment
center for fatigue.36,45 The significance of both moderators needs to
be replicated in further studies to obtain a stronger level of evidence.
Moreover, our literature search was not specifically focused on
cancer-related fatigue but on quality of life, and not all authors of eligi-
ble studies were able or willing to share their data. Additionally, we
used data that were available in the POLARIS database. Consequently,
this could have introduced data availability bias,49 as the studies may
not fully reflect the entire evidence base of studies on the efficacy of
psychosocial interventions on fatigue. In particular, our results on
moderators with small subsets of studies might have been different
(and more certain) if more recent studies had been included. More
studies would also facilitate forming more specific subgroups, for
instance by specifying data on specific types of surgery, radio-,
chemo- and/or hormone therapy. The effect sizes of the psychosocial
interventions in this study on fatigue in patients with breast and pros-
tate cancer were smaller compared to the moderate effect size
reported in a meta-analysis with more up-to-date studies.2 However,
even if a data availability bias would have resulted in an over- or
underestimation of the overall intervention effect, our results on mod-
erator effects could still be valid.
5.2 | Clinical implications
Findings of this paper indicate that psychological interventions for
fatigue can be used across subgroups of patients with non-metastatic
breast or prostate cancer, with CBT being particularly effective for
patients with breast cancer. Previous studies have already shown that
more broadly focused psychosocial interventions can result in
improvement across a range of outcomes like distress,33,34 subjective
well-being,42,43 and quality of life.33,38,43,46 If fatigue is a main symp-
tom, a specific focus of interventions on decreasing fatigue seems
1780 ABRAHAMS ET AL.
beneficial for breast cancer patients with clinically relevant levels of
fatigue.
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F IGURE A1 Flow-chart of included studies. Note: k, number of studies;
n, number of patients
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TABLE A1 Baseline and post-intervention levels of fatigue
Patients with breast cancer Patients with prostate cancer
Intervention
(N = 584) Control (N = 547)
Intervention











SF-36 vitality subscale, range 0-100
Baseline 164 48.7 (20.4) 160 46.7 (18.9) 460 45.3 (18.9) 465 44.3 (18.0)
Post-intervention 138 41.5 (20.1) 143 44.6 (19.4) 411 48.4 (19.7) 439 49.2 (19.9)
Clinically relevant level of fatigue (cut-off score ≤50)
at baseline
85 52% 77 48% 201 44% 194 42%
QLQ-C30 fatigue subscale, range 0-100
Baseline 161 30.9 (22.8) 126 33.5 (23.9) 22 30.3 (27.0) 17 21.6 (18.6)
Post-intervention 149 27.4 (22.6) 114 31.4 (22.6) 20 22.2 (21.6) 19 25.1 (20.2)
Clinically relevant fatigue (cut-off score ≥40) at
baseline
49 30% 46 9% 5 22% 3 14%
POMS fatigue subscale, range 0-28
Baseline 93 10.6 (7.0) 97 10.0 (7.5) - - - -
Post-intervention 79 9.5 (7.0) 85 9.2 (7.2) - - - -
CIS fatigue severity subscale, range 8-56
Baseline 51 30.4 (15.6) 49 29.5 (15.3) 16 25.0 (15.1) 18 20.3 (11.0)
Post-intervention 50 23.5 (12.3) 45 30.4 (14.2) 16 17.7 (10.5) 18 22.7 (11.8)
Clinically relevant fatigue (cut-off score ≥35) at
baseline
23 45% 19 39% 4 25% 3 17%
MFI general fatigue score, range 1-5
Baseline 27 2.9 (0.7) 30 2.7 (0.6) - - - -
Post-intervention 23 2.5 (0.7) 27 2.5 (0.5) - - - -
Note: Higher scores indicate higher symptom levels.
Abbreviations: CIS fatigue, checklist individual strength, subscale fatigue severity; MFI global fatigue, multidimensional fatigue inventory, global fatigue
score; N, sample size; POMS, profile of mood state; QLQ-C30 fatigue, European Organization for Research and Treatment of Cancer Quality of Life Ques-
tionnaire – Core 30 fatigue subscale; SCL, Symptom Checklist; SF-36, Short Form-36 Item Health Survey.
aNot all subjects were assessed for depressive symptoms, anxiety symptoms, pain, or insomnia.
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TABLE A2 Baseline levels of depressive symptoms, anxiety, pain, and insomnia
Patients with breast cancer Patients with prostate cancer
Intervention (N = 584) Control (N = 547) Intervention (N = 500) Control (N = 508)
Na Mean (SD)/% Na Mean (SD)/% Na Mean (SD)/% Na Mean (SD)/%
Depressive symptoms
HADS depression subscale, range 0-21 348 4.2 (3.7) 304 4.0 (3.4) 22 2.7 (2.4) 18 3.2 (3.2)
POMS depression subscale, range 0-60 93 7.3 (8.6) 98 6.4 (10.5) - - - -
BDI, range 0-63 15 14.8 (8.3) 13 10.2 (4.5) - - - -
WHQ depression subscale, range 0-1 47 0.4 (0.3) 46 0.5 (0.3) - - - -
SCL depression subscale, range 0-72 36 21.4 (5.2) 34 20.6 (4.1) 16 22.5 (6.8) 18 21.2 (6.1)
Anxiety
HADS anxiety subscale, range 0-21 350 6.4 (4.3) 302 6.5 (4.5) 21 4.0 (3.2) 18 4.2 (4.1)
STAI state subscale, range 20-80 15 44.5 (13.1) 13 11.2 (3.1) - - - -
POMS anxiety subscale, range 0-36 92 8.3 (6.5) 98 6.3 (6.3) - - - -
WHQ anxiety subscale, range 0-1 47 0.3 (0.3) 46 0.5 (0.3) - - - -
SCL anxiety subscale, range 0-40 36 13.6 (3.2) 34 13.6 (4.0) 16 14.1 (3.7) 18 12.0 (2.5)
Pain
QLQ-C30 pain subscale, range 0-100 254 24.5 (25.1) 208 22.9 (23.4) 38 21.1 (27.9) 36 17.1 (26.3)
SF-36 pain subscale, range 0-100 167 33.7 (27.0) 162 29.6 (24.9) 491 13.4 (19.9) 495 13.6 (20.2)
Insomnia
QLQ-C30 insomnia subscale, range 0-100 255 36.5 (30.7) 208 36.3 (32.7) 38 22.8 (29.1) 36 14.8 (20.2)
Note: Higher scores indicate higher symptom levels.
Abbreviations: BDI, beck depression inventory; HADS, Hospital Anxiety and Depression Scale; N, sample size; POMS, profile of mood state; QLQ-C30,
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30; SCL, Symptom Checklist; SF-36, Short Form-36
Item Health Survey; STAI, State-Trait Anxiety Inventory; WHQ, Women's Health Questionnaire.
aNot all subjects were assessed for depressive symptoms, anxiety symptoms, pain, or insomnia.
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